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Purpose: Enteric glial cells (EGCs) exert a critical role in the structural integrity, defense, 
and metabolic function of enteric neurons. Diabetes mellitus is a chronic disease char-
acterized by metabolic disorders and chronic autonomic neuropathy. Quercetin supple-
mentation, which is a potent antioxidant, has been used in order to reduce the effects of 
diabetes-induced oxidative stress. The purpose of this research was to investigate the 
effects of quercetin supplementation in the drinking water at a daily dose of 40 mg on 
the glial cells and neurons in the jejunum of diabetic rats.
Materials and methods: Twenty 90-day-old male adult Wistar rats were split into four 
groups: normoglycemic control (C), normoglycemic control supplemented with querce-
tin (Q), diabetic (D), and diabetic supplemented with quercetin (DQ). After 120 days, the 
jejunums were collected, and immunohistochemical technique was performed to label 
S-100-immunoreactive glial cells and HuC/D-immunoreactive neurons.
results: An intense neuronal and glial reduction was observed in the jejunum of dia-
betic rats. Quercetin displayed neuroprotective effects due to reduced cell body areas of 
neurons and glial cells in Q and DQ groups compared to their controls (C and D groups). 
Interestingly, quercetin prevented the glial and neuronal loss with a higher density for the 
HuC/D-immunoreactive neurons (23.06%) and for the S100-immunoreactive glial cells 
(14.55%) in DQ group compared to D group.
conclusion: Quercetin supplementation promoted neuroprotective effects through the 
reduction of neuronal and glial body areas and a slight prevention of neuronal and glial 
density reduction.
Keywords: diabetes mellitus, enteric nervous system, glia, neuroprotection, quercetin
inTrODUcTiOn
The incidence of diabetes mellitus (DM) increases every year and has been associated with the 
growth of obesity in the worldwide population (1, 2). The long-term presence of hyperglycemia 
can promote an autonomic neuropathy that affects the parasympathetic and sympathetic nerves. 
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Furthermore, DM is associated with functional disorders of 
several organs, including the gastrointestinal tract. The diabetic 
neuropathy also affects the enteric nervous system (ENS), which 
promotes severe changes in the functional digestive activity (e.g., 
motor, secretory/absorptive, and vascular changes) (3). In par-
ticular, the ENS is a subdivision of the autonomic nervous system 
that comprises a neuronal network distributed throughout the 
digestive system, together with enteric glial cells (EGCs), which 
are non-neuronal cells and the major constituent of the ENS 
involved in the physiological activity and homeostasis mainte-
nance of the gastrointestinal tract (4, 5).
Several researches have described that EGCs exert a structural 
supportive role to the enteric neurons and are also responsible for 
their survival and maintenance (5). The EGCs express the S100 
protein (calcium-binding protein), a panglial marker that has 
been intensively studied and observed through the immunohis-
tochemical techniques (6). The S100 protein exerts neurotrophic 
activity through the growth induction of neuronal extensions as 
well as dendrites and axons, and in the participation of the enteric 
neuronal survival. In addition, S100 protein is also involved in 
the regulation of specific intracellular signaling pathways, such as 
the regulation of protein phosphorylation, enzymatic activities, 
Ca2+ homeostasis, cytoskeletal stability, and apoptosis induction 
(7). The EGCs are also involved in the metabolic support of the 
SNE, enteric neurotransmission, motility, and bowel inflamma-
tory diseases (8, 9).
Neurodegeneration is characterized by the damage on the 
structure, function, and number of neurons, which results in 
essential functional deficiencies (10). The reduction of the enteric 
neuronal and glial density (11–13) has been well established in 
the diabetic neuropathy due to an increased oxidative stress, 
which leads to an imbalance between the production of reactive 
oxygen species (ROS) and the cellular antioxidant defense system 
(14). Furthermore, morphometric analyses of the neuronal and 
glial body area have also been studied for a better evaluation of 
the diabetic neuropathy and its neurological consequences.
Therapeutic approaches have demonstrated that the diet sup-
plementation with antioxidants reduces the oxidative stress or 
inhibits the aldose reductase, an enzyme that displays a crucial 
role in the treatment of diabetes and its neurological complica-
tions (15). Flavonoids are a group of polyphenols that exert a 
remarkable antioxidant activity, and they have been substantially 
used for the treatment of several diseases (16). Quercetin is 
one of the major natural polyphenolic flavonoids, which exerts 
beneficial pharmacological effects, such as anti-hypertensive, 
antidepressant, anti-arrhythmic, anti-hyperalgesic, hypocho-
lesterolemic, anti-hepatotoxic, anticarcinogenic, anti-ulcer, 
antiviral, antithrombotic, anti-ischemic, anti-inflammatory, and 
anti-allergy effects (17–20).
Quercetin neuroprotective effects have been described in 
some neurodegenerative diseases such as Alzheimer’s disease, 
Parkinson’s disease, and Huntington’s disease (10). Furthermore, 
it has recently been reported that quercetin demonstrated 
neuroprotective effects in the cecum and duodenum in diabetes 
experimental models (21, 22). Thus, the purpose of this inves-
tigation was to evaluate the quercetin supplementation effects 
during 120 days in the drinking water at a dose of 40 mg/day 
on the general neuronal population and the glial cells of jejunal 
myenteric plexus of diabetic rats.
MaTerials anD MeThODs
animals
All procedures described in the current study are in accordance 
with the ethical principles adopted by the SBCAL (Brazilian 
Society of Sciences Laboratory Animal) and have previously 
been submitted to analysis by the Ethics Committee on Animal 
Experiments of the State University of Maringá (UEM) (accept-
ance 053/2009).
Twenty 90-day-old male adult Wistar rats (Rattus norvegicus) 
from Central Viverium (UEM) were used. The experiment of 
DM contained four groups with five rats per group: normogly-
cemic control (C), normoglycemic control supplemented with 
quercetin (Q), diabetic (D), and diabetic supplemented with 
quercetin (DQ).
Animals were maintained in individual cages for a period of 
120 days in a vivarium with a 12-h light: dark cycle and room 
temperature (24 ±  2°C), receiving food and water ad  libitum. 
All groups received balanced standard Nuvital feed (Nuvilab, 
Colombo, Parana, Brazil). For the experimental supplementa-
tion of Q and DQ groups, water supplemented with quercetin 
(Cromofarma, São Paulo, Brazil) was given at a dose of 40 mg/
day solubilized in sodium hydroxide (NaOH) at pH 7.4. The 
animals of C and D groups, the non-supplemented groups, only 
received the vehicle that contained water diluted in NaOH.
For calculation of the quercetin dose, a preliminary evalua-
tion of water intake of Q and DQ groups was performed during 
three consecutive days in order to obtain the average amount of 
water consumed per animal.
The diabetes experiment was induced after a 14-h fasting 
through the intravenous injection of streptozotocin (35 mg/kg 
body weight; Sigma, St. Louis, MO, USA) dissolved in a citrate 
buffer solution at a pH 4.5 (10 mM). After 4 days of DM induc-
tion, blood glucose concentrations were measured by using the 
glucose oxidase method to confirm the establishment of the 
experimental model (23). Only the animals with blood glucose 
concentrations above 250 mg/dL were kept in D and DQ groups.
collection and Processing of the Material
After a period of 120  days, the animals were weighed and 
euthanized under anesthesia with thiopental (40  mg/kg body 
weight, i.p.; Abbott Laboratories, Chicago, IL, USA). The blood 
was collected by using cardiac puncture for the blood glucose 
measurements (20). After celiotomy, the samples were collected 
from all the animals, and then washed with phosphate-buffered 
saline (PBS, 0.1M, pH 7.4), gently inflated with Zamboni’s fixa-
tive solution to fill the space previously occupied by the stool, 
thus avoiding the jejunal stretching. After that, the jejunums were 
maintained for 18 h in the same solution at 4°C. After fixation, 
the samples were carefully opened along the mesenteric border 
and successively rinsed with 80% ethanol in order to completely 
remove the fixative excess. Then, the dehydrations were sequen-
tially performed with ethanol concentration of 95 and 100%, 
TaBle 1 | Density per unit area (cm2) of huc/D-immunoreactive 
myenteric neurons (intraganglionar, extraganglionar, and total) in the 
jejunum obtained from the following groups: normoglycemic control (c), 
normoglycemic control supplemented with quercetin (Q), diabetic (D), 
and diabetic supplemented with quercetin (DQ).
intraganglionar extraganglionar Total s100/hu
C 26,646.7 ± 1,341.9 198.4 ± 9.2 26,845.1 ± 1,343.5 2.33 ± 0.05
Q 22,491.8 ± 1,610.8 176.6 ± 25.8 23,008.2 ± 1,851.7 2.37 ± 0.09
D 16,741.8 ± 739.6** 163.0 ± 20.2** 16,904.9 ± 750.0** 2.37 ± 0.02
DQ 20,633.2 ± 873.3 171.2 ± 14.6 20,804.3 ± 876.9 2.22 ± 0.06
Results were expressed as mean ± SE.
n = 5 rats per group.
**Significant difference between D vs C groups according to Tukey’s test (p < 0.05).
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followed by clarification in xylene. After that, the rehydration 
was performed by using ethanol at decreasing concentrations 
(100, 90, 80, and 50%). The tissues were stored at 4°C in PBS 
with 0.08% sodium azide.
The samples were microdissected under a stereomicroscope 
in order to obtain the whole mounts of muscularis tunica by the 
removal of the mucosal and submucosal layers. The tissues were 
double stained by immunohistochemistry to label HuC/D and 
S-100 proteins (24, 25).
Double staining immunohistochemistry 
for the huc/D and s100 Proteins
Twenty whole mounts were initially rinsed twice in PBS solution 
that contained 0.5% Triton X-100 (Sigma) for 10 min. After that, 
the tissues were incubated for 1 h with a blocking solution that 
contained 0.5% Triton X-100, 2% bovine serum albumin (BSA) 
(Sigma) with 10% goat serum in PBS solution. After blockage, 
the samples were incubated for 48 h at 4°C with a solution that 
contained specific primary antibodies for HuC/D (produced in 
mice, 1:500; Molecular Probes, Carlsbad, CA, USA) and S100 
(produced in rabbits, 1:200; Sigma). The jejunums were rinsed 
twice in PBS solution that contained 0.5% Triton X-100 for 
10 min and incubated for 2 h at room temperature with the fol-
lowing secondary antibodies: Alexa Fluor 488 IgG anti-mouse 
produced in donkey (1:500; Molecular Probes) for labeling the 
HuC/D protein, and Alexa Fluor 546 IgG anti-rabbit produced 
in goat (1:500; Peninsula Labs, Torrance, CA, USA) for labeling 
the S100 protein. After incubation, the whole mounts were also 
rinsed twice in PBS solution, mounted on slides with antifade 
medium, and stored in refrigeration at 4°C. For the negative 
control, the immunolabeling was performed without presence 
of primary antibody.
immunohistochemistry for Quantitative 
analysis
To quantify the HuC/D-immunoreactive myenteric neurons 
(HuC/D-IR) and the S100-immunoreactive glial cells (S100-IR), 
the images were obtained and randomly counted and measured 
in the intermediate region of the jejunum. For that, the bowel 
circumference was divided into three regions: mesenteric, inter-
mediate, and antimesenteric (26).
Images were captured by using the high-resolution camera 
AxioCam (Zeiss, Jena, Germany) coupled to a light microscope 
Axioskop Plus (Zeiss), and digitalized into a computer with 
the AxioVision Software version 4.1. The image analysis of the 
Image-Pro Plus version 4.5.0.29 Software (Media Cybernetics, 
Silver Spring, MD, USA) was used for the neuronal and glial 
quantification.
For each animal, all neurons and EGCs were counted in the 
32 images captured with 20× objective lens. In addition, the 
myenteric glial cells and neurons observed inside and outside of 
the myenteric ganglion were considered as intraganglionar and 
extraganglionar, respectively. The sum of all the neurons observed 
in the field (intraganglionar and extraganglionar) comprised the 
total number of neurons. The area of each image was measured 
by using the Image-Pro Plus Software, which was approximately 
of 0.23 mm2. Neuronal and glial densities were expressed as the 
number of neurons and glial cells per square centimeter.
immunohistochemistry for Morphometric 
analysis
Cell body areas of HuC/D-IR neurons and S100-IR glial cells 
were measured with the same images used for the quantitative 
analysis. The areas (square micrometer) of neuronal and glial 
body areas were measured by using an Image-Pro Plus Software, 
with a total of 100 cell body areas for the neurons and glial cells 
measured per animal.
statistical analysis
Data were statistically analyzed by using the Statistica 7.1 and 
GraphPad Prism 5.1 Software and were expressed as mean ± SE. 
Morphometric data were set in delineation blocks, followed and 
analyzed by the Tukey’s test. For the other data, the one-way 
analysis of variance (ANOVA) was performed, followed by the 
Tukey’s test. The p values <0.05 were considered statistically 
significant.
resUlTs
Physiological Data
After 120  days of diabetes induction, the animals of D 
(564.4 ± 45.33 mg/dL) and DQ groups (542.4 ± 46.18 mg/dL) 
exhibited an increased hyperglycemia compared to the C group 
(149.1 ± 25.32 mg/dL) (p < 0.001). However, quercetin supple-
mentation promoted unchanged blood glucose concentrations in 
Q group (144.7 ± 16.33 mg/dL) (p > 0.05). Furthermore, the body 
weight of normoglycemic animals was 521.1 ± 15.07 g (C group) 
and 500.0 ± 12.46 g (Q group) (p > 0.05). However, the diabetic 
rats of D and DQ groups exhibited a reduced body weight of 
331.0 ± 16.39 and 321.7 ± 20.25 g, respectively (p < 0.05).
Quantitative analysis
In the myenteric plexus, D group exhibited a density reduction of 
HuC/D-IR neurons (intraganglionar, extraganglionar, and total) 
compared to the C group (Table 1; p < 0.05). In addition, the 
myenteric neuronal density seen in DQ group demonstrated a 
non-significant statistical difference compared to the D group 
(p > 0.05).
TaBle 2 | Density per unit area (cm2) of s100-immunoreactive myenteric 
glial cells (intraganglionar, extraganglionar, and total) in the jejunum 
obtained from the following groups: normoglycemic control (c), 
normoglycemic control supplemented with quercetin (Q), diabetic (D), 
and diabetic supplemented with quercetin (DQ).
intraganglionar extraganglionar Total
C 52,260.9 ± 3,257.4 10,214.7 ± 821.4 62,475.5 ± 3,305.0
Q 45,005.4 ± 2,248.7 8,864.1 ± 735.1 53,885.9 ± 2,811.9
D 32,807.1 ± 1,418.6** 7,353.3 ± 703.6** 40,160.3 ± 1,892.5**
DQ 39,141.3 ± 1,223.6 6,861.4 ± 179.3 46,002.7 ± 1,227.6
Results were expressed as mean ± SE.
n = 5 rats per group.
**Significant difference between D vs C groups according to Tukey’s test (p < 0.05).
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There were no significant differences in the S100/Hu ratio 
when compared with all the groups (p > 0.05; Table 1).
Density of S100-IR enteric glial cells (intraganglionar, 
extraganglionar, and total) was significantly reduced in D group 
compared to the C group (Table 2; p > 0.05). In contrast, non-
significant differences were seen between D and DQ groups 
(p < 0.05).
cell Body area of the huc/D-ir Myenteric 
neurons
Representative photomicrographs of HuC/D-IR myenteric neu-
rons and myenteric glial cells are shown in Figure 1.
Quercetin supplementation promoted a decreased neuronal 
body area of HuC/D-IR myenteric neurons (p <  0.007) in Q 
group compared to the C group by observing the displacement 
of the distribution curve to the left (Figures  2A,B). Unlike Q 
group, the diabetes (D group) induced an increased neuronal 
body area for the HuC/D-IR neurons (p < 0.03) (Figure 2) in 
relation to the C group. Furthermore, quercetin supplementation 
in the diabetic animals (DQ group) restored the neuronal body 
area similar to those observed in the control (C group; p > 0.05) 
(Figure 2C). This result was evident on observing the displace-
ment of the distribution curve to the left when the DQ group was 
compared to D (Figure 2D).
cell Body area of the s100-ir Myenteric 
glial cells
The glial body area was lower in Q group compared to the C 
group (p < 0.05; Figure 3). However, C, D, and DQ groups dem-
onstrated similar data in the glial body area (p > 0.05; Figure 3).
DiscUssiOn
The experimental model of diabetes was confirmed by the high 
blood glucose concentrations observed in D and DQ groups. 
In addition, remarkable clinical features of DM were also seen 
throughout the experiment, such as weight loss, overeating, 
polydipsia, polyuria, hyperglycemia, and increased irritability 
after 7 days of DM induction, as reported by Furlan et al. (27). 
The body weight loss in the diabetic animals (D group) suggests 
a disorder in the synthesis and storage of energy reserves (28). 
However, quercetin did not prevent the body weight loss in the 
rats of DQ group compared to the D group as well as the plasma 
glucose levels remained unaltered. Thus, high blood glucose 
levels persisted throughout the experiment and its consumption 
was reduced in insulin-dependent tissues, thereby it might be 
suggested that quercetin exerts no interference in the signaling 
pathways that lead to a weight gain or other signaling pathways 
associated with the mobilization of energetic reserves in the 
diabetic animals (22).
Reduction of neuronal and glial density was observed in dia-
betic animals; similar results have been described in the literature 
(29–34). Enteric neuropathy is related to intracellular signaling 
disorders associated with quantitative and neurochemical 
alterations of the enteric neurons. These changes may explain 
the neuronal density loss and the important clinical dysfunc-
tions of neurological alterations of DM (35). Furthermore, it has 
been proposed that the induction of oxidative stress might be a 
determinant of the neuronal damage in the diabetes as well as 
alterations in the cellular metabolic pathways, which may result 
in programed cell death through the apoptosis and autophagy 
(36–40).
In this study, the density data are reinforced by the results 
obtained in the morphometric analysis, since the diabetic rats 
(D group) exhibited the highest neuronal body areas. The hyper-
trophy of the neuronal size of diabetic rats might be associated 
with an increased enzymatic synthesis and as a compensatory 
mechanism against the neuronal density reduction. An increased 
functional neuronal activity likely occurs in order to balance the 
neuronal density loss and maintain the functional intestinal 
activity closer to the ideal. This feature may explain the increase 
of neurotransmitter production due to a compensatory effect 
of neuronal loss in DM (41–43). Furthermore, it has also been 
suggested that a defective axonal transport of neuronal proteins 
that are synthesized inside the neuronal body can explain the 
accumulation of these proteins (44). Other approach is the 
accumulation of oxidative material inside the cell that results in 
swelling of the enteric neurons (45).
In D group, the glial density was significantly lower than C 
group, although the glia/neuron ratio remained unchanged. In 
addition, diabetes-induced neuronal loss was accompanied by a 
proportional reduction of the glial cells. According to Burnstock, 
the glia/neuron ratio appears in a 2:1 relation and has been main-
tained in different experimental groups (46). Other essential roles 
of EGCs have been described such as detoxification of metabo-
lites produced from the degradation of neurotransmitters and 
glutamate of extracellular medium as well as the EGCs, which are 
involved in the glutathione production for its consumption and 
exportation to the neurons, and in the participation in inflamma-
tory processes that affect the nervous tissues (47, 48).
Although the glial density reduction has occurred, the glial 
body area was maintained. Few researches in the literature 
have analyzed the size of the glial cells in conditions of dis-
eases and inflammatory processes. Our group’s research has 
already observed that diabetes leads to size reduction of EGCs 
(49), although hypertrophy occurs in the enteric neurons. 
Furthermore, EGCs provide mechanical structural support to 
the neurons, in addition to glial cells can also release numerous 
neurotrophic factors that control their development, survival, 
FigUre 1 | representative photomicrographs that illustrate the whole mounts of jejunal myenteric plexus stained by immunohistochemical 
technique for huc/D-immunoreactive neurons (first column) and s-100- immunoreactive glial cells (middle column). The third column illustrates the 
overlapping of the images of the neurons and enteric glial cells. The following groups were used: normoglycemic control (C), normoglycemic control 
supplemented with quercetin (Q), diabetic (D), and diabetic supplemented with quercetin (DQ). Scale bar = 20 µm.
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and differentiation, and these cells release reduced glutathione or 
glial cell-derived neurotrophic factor (GDNF) that activates the 
neuropeptide Y and antioxidant system, thus protecting against 
the neuronal death (5, 50, 51). Therefore, the EGCs loss observed 
in D group might be closely associated with the neuronal degen-
eration and gastrointestinal motility dysfunctions (51, 52).
Therapy with antioxidants has intensively been studied to pre-
vent the enteric neuropathy progress by acting in the metabolic 
pathways that generate oxidative stress and/or directly on the 
scavenging of ROS. Quercetin, a bioflavonoid antioxidant, has 
been described as a chelating agent of metals and free radical 
scavenger (53). Furthermore, quercetin neuroprotective effects 
have also been studied in the diabetes and its complications 
induced by the oxidative stress (21, 22).
The comparison of the density of the HuC/D-IR myenteric 
neurons and S100-IR glial cells between the DQ and D groups 
has not revealed a significant statistical difference. However, the 
supplementation with quercetin showed a preservation of the 
myenteric neurons, since a total neuronal and glial density of 
23.06 and 14.55% was higher in the DQ group than D group, 
respectively. Although quercetin slightly prevents the loss of 
enteric neurons, this bioflavonoid promotes a preservation of 
the neuronal density in most animals when analyzed individually 
(data not shown).
Neuroprotection effects were observed in the neuronal 
body size in the DQ group. The quercetin protective results 
were obtained in DQ group possibly due to scavenging action 
mechanisms underlying the neutralization of ROS and, in 
FigUre 2 | Morphometric results of huc/D-immunoreactive myenteric neurons. The left column demonstrates (a,c) the mean ± SE of the neuronal body 
areas (square micrometer) and the right column illustrates the relative frequency distribution (B,D) of the neuronal body areas in the following groups: normoglycemic 
control (C), normoglycemic control supplemented with quercetin (Q), diabetic, and (D) diabetic supplemented with quercetin (DQ). n = 5 mice per group. *p < 0.05 
vs C group; **p < 0.05 vs C group; #p < 0.05 vs D group.
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FigUre 3 | Morphometric results of s100-immunoreactive glial cells of the myenteric plexus. The left column shows (a,c) the mean ± SE of the areas 
of the enteric glial cells (square micrometer), and the right column illustrates the relative frequency distribution (B,D) of glial body areas in the following groups: 
normoglycemic control (C), normoglycemic control supplemented with quercetin (Q), diabetic (D), and diabetic supplemented with quercetin (DQ). n = 5 mice per 
group. *p < 0.05 vs C group.
turn, prevention of oxidative stress-induced neuronal dam-
age, thereby acting on the preservation of cellular enzymatic 
machinery (21, 22).
With regard to the neuronal and glial densities between 
C and Q groups, similar data were seen. For this reason, these 
results suggest that the daily dosage of 40 mg quercetin displayed 
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